Sign in

XBIO on Nasdaq

Xenetic Biosciences (United States)

Logo: xeneticbio.com4

Xenetic Biosciences (United States) is an American pharmaceutical preparations company based in Lexington.1 It was founded in 2014.1 Its shares trade on Nasdaq under the symbol XBIO.1

Price unavailable

Last updated Oct 21, 2026.

Overview

2014Founded1

Compare with TherapeuticsMD, Inc., Upstream Bio, Inc. or Aptevo Therapeutics Inc., or pick any stock.

  • TickerXBIO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLexington1
  • Websitewww.xeneticbio.com
  • Incorporated inNV5
  • Business address945 Concord St., Framingham, Ma 017015
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation3
  • LEI5493002WV0KYX8JXAH523
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O WESTWARD LAW LLC, 89120 Las Vegas, United States3
  • Registered withBusiness Center (Secretary of State), E0450492011-83

See how the biggest companies compare on our leaderboards

Xenetic Biosciences (United States) image from its website
Image: xeneticbio.com4

The outcome and timing of the strategic review process being conducted by the Company’s Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process; the Company’s inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors; the potential for disruption to our business resulting from the review process; and potential adverse effects on the Company’s stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company’s current business operations, anticipated business strategy and product development plans.7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-95.2%Operating margin8
-90.1%Net margin8
19.0%Revenue growth, 20258
-36.2%Return on equity8

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$3.1M

Out of $3.0M in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$3.0M in 2025+17341% since 2019
0$1.0M$2.0M$3.0M2019: $17.1K$17.1K20192020: $436.9K$436.9K2020+2460%2021: $1.2M$1.2M2021+166%2022: $1.7M$1.7M2022+47%2023: $2.5M$2.5M2023+49%2024: $2.5M$2.5M2024−2%2025: $3.0M$3.0M2025+19%
Operating income9101112138-$2.8M in 2025−78% since 2019
-$15.0M-$10.0M-$5.0M02019: -$12.9M-$12.9M20192020: -$13.9M-$13.9M2020+8%2021: -$5.7M-$5.7M2021−59%2022: -$6.7M-$6.7M2022+17%2023: -$4.5M-$4.5M2023−33%2024: -$4.2M-$4.2M2024−7%2025: -$2.8M-$2.8M2025−33%
Net income9101112138-$2.7M in 2025−79% since 2019
-$15.0M-$10.0M-$5.0M02019: -$12.8M-$12.8M20192020: -$10.9M-$10.9M2020−15%2021: -$5.6M-$5.6M2021−48%2022: -$6.6M-$6.6M2022+16%2023: -$4.1M-$4.1M2023−37%2024: -$4.0M-$4.0M2024−4%2025: -$2.7M-$2.7M2025−32%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Royalty revenue$3.0M$2.5M
Total revenue$3.0M$2.5M
Research and development-$3.1M-$3.3M
General and administrative-$2.7M-$3.4M
Total operating costs and expenses-$5.8M-$6.7M
Loss from operations-$2.8M-$4.2M
Other income (expense)$5.7K-$5.7K
Interest income, net$148.0K$249.9K
Total other income, net$153.7K$244.2K
Net loss-$2.7M-$4.0M
Basic net loss per share-$1.58-$2.57
Diluted net loss per share-$1.58-$2.57
Weighted-average shares of common stock outstanding, basic1.7M shares1.5M shares
Weighted-average shares of common stock outstanding, diluted1.7M shares1.5M shares

Compare Xenetic Biosciences (United States) with another company

Corporate structure

Xenetic Biosciences (United States) sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Xenetic Biosciences (United States)

  • MJL Manager LLC Filed SCHEDULE 13G on Xenetic Biosciences (United States), latest Sep 18, 2026 (2 filings since May 29, 2026)
  • RENAISSANCE TECHNOLOGIES LLC Filed SCHEDULE 13G/A on Xenetic Biosciences (United States), latest May 14, 2026 (2 filings since Feb 12, 2026)
  • CLS Therapeutics, LLC Filed SC 13D/A on Xenetic Biosciences (United States), latest Mar 18, 2024 (4 filings since Oct 21, 2022)
  • Xenetic Biosciences (United States) Framingham, Massachusetts, United States
    • Xenetic Bioscience, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Xenetic Biosciences (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

We rent office space at an office share location at 945 Concord Street in Framingham, Massachusetts. The lease agreement is for 6-months through June 30, 2026. We believe that this space is adequate for our current needs and that if additional space is required, it can be obtained at commercially reasonable terms nearby.

Item 2 of the 10-K filed Mar 12, 2026.7

Leadership

Who has led Xenetic Biosciences (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Scott Maguire2016–2017
  2. Jeffrey F. Eisenberg2017–2023
  3. James F. Parslow2024–now

Chief financial officer

  1. James F. Parslow2017–now

Chief operating officer

  1. Jeffrey F. Eisenberg2016
201520202025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorAlexey Vinogradov named May 4, 2022 to Oct 13, 202234

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Xenetic Bioscience, Inc. Delaware6

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • General Sales & Leasing, Inc.Feb 27, 2013 to Jan 10, 20145
  • GENERAL AIRCRAFT INC.Nov 21, 2011 to Feb 12, 20135

Timeline

  1. Sep 23, 20268-K Regulation FD disclosure35
  2. Sep 16, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure36
  3. Aug 7, 20268-K Results of operations37
  4. May 13, 20268-K Results of operations38
  5. Apr 24, 20268-K Executive or director change39
  6. Mar 13, 20268-K Results of operations40
  7. Jan 9, 20268-K Other events41
  8. Dec 11, 20258-K Regulation FD disclosure42
  9. Nov 13, 20258-K Results of operations43
  10. Oct 14, 20258-K Entered a material agreement; Other events44
  11. Aug 13, 20258-K Results of operations45
  12. May 14, 20258-K Results of operations46
  13. Jun 21, 2024New chief executive James F. Parslow becomes CEO16
  14. Oct 30, 2017New chief executive Jeffrey F. Eisenberg becomes CEO17
  15. Dec 23, 2016New chief executive Michael Scott Maguire becomes CEO18
  16. 2014Founded Founded1

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202647

When it reported results

  1. Aug 7, 2026Reported quarterly or annual results37
  2. May 13, 2026Reported quarterly or annual results38
  3. Mar 13, 2026Reported quarterly or annual results40
  4. Nov 13, 2025Reported quarterly or annual results43
  5. Aug 13, 2025Reported quarterly or annual results45
  6. May 14, 2025Reported quarterly or annual results46
  7. Mar 19, 2025Reported quarterly or annual results48
  8. Nov 13, 2024Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

147 filings to the SEC since October 2021: 11 annual reports, 15 quarterly reports, 48 major events, 35 insider forms, 8 large holders, 2 private raises, 28 other. The latest 20:

  1. Sep 23, 20268-K CURRENT REPORT EDGAR
  2. Sep 18, 2026SCHEDULE 13G EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Aug 7, 20268-K EDGAR
  5. Aug 6, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  6. May 29, 2026SCHEDULE 13G EDGAR
  7. May 14, 2026SCHEDULE 13G/A EDGAR
  8. May 13, 20268-K EDGAR
  9. May 12, 202610-Q QUARTERLY REPORT FOR MARCH 2026 EDGAR
  10. Apr 24, 202610-K/A FORM 10-K FOR DEC 2025 AMENDMENT 1 EDGAR
  11. Apr 24, 20268-K CURRENT REPORT EDGAR
  12. Apr 23, 20264 EDGAR
  13. Mar 13, 20268-K CURRENT REPORT EDGAR
  14. Mar 12, 202610-K FORM 10-K FOR DEC 2025 EDGAR
  15. Feb 12, 2026SCHEDULE 13G EDGAR
  16. Jan 9, 20268-K EDGAR
  17. Jan 5, 20264 EDGAR
  18. Jan 5, 20264 EDGAR
  19. Jan 5, 20264 EDGAR
  20. Jan 5, 20264 EDGAR

The 147 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Jeffrey F. Eisenberg,$201.8K$673.1K53
2024Dr. Curtis Lockshin,$167.0K$554.1K53
2024James Parslow,60$378.4K$481.2K53
2023Former ChiefExecutive Officer$404.2K$563.5K53
2023Former Chief Scientific Officer$329.2K$435.8K53
2023Interim Chief Executive Officer &Chief Financial Officer$329.2K$433.7K53

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.4M 2022–2022
Money received by yearMoney received by year, 2022–2022: $1.4M in all. Private raises (Form D) $1.4M.$0$500K$1M$1.5M2022 · Private raises (Form D): $1.4M2022
Figures by year
YearPrivate raises (Form D)Total
2022$1.4M$1.4M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 12, 2022Raised $488,835 in a private offering of equity34 Form D: 1 investor so far Form D
  2. Apr 26, 2022Raised $866,250 in a private offering of equity54 Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC117,440$341.8K0.0%−20,000
Geode Capital Management, LLC17,423$50.7K0.0%−4,018
Vanguard Capital Management LLC12,681$36.9K0.0%+5,950
SBI Securities Co., Ltd.1,000$2.9K0.0%New
Tower Research Capital LLC (TRC)696$2.0K0.0%−110
Morgan Stanley150$4370.0%New
JTC Employer Solutions Trustee Ltd2,700$80.0%No change
Darwin Wealth Management, LLC2$50.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Xenetic Biosciences (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARXenetic Biosciences, Inc.2
  • CIK0001534525
  • Employer ID (EIN)45-29529627
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company7
  • Incorporated inNevada7
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address945 Concord St., Framingham, MA 017012
  • Phone781-778-77202
  • Shares outstanding2,343,181 as of Jul 31, 202615
  • Public float$5.1M as of Jun 30, 20257
  • AuditorCBIZ CPAs P.C., Hartford, CT PCAOB ID 199; no auditor attestation of internal control over financial reporting7
  • On EDGAR sinceNov 21, 20112
  • Filings484 in all: 8-K (134), 4 (70), 10-Q (44), CORRESP (29), 10-K/A (17), 3 (17), S-1/A (17), 10-K (15)2
    All 45 form types

    UPLOAD (14), 425 (9), DEF 14A (9), EFFECT (9), 8-K/A (7), SC 13G (7), 424B5 (6), NT 10-Q (6), 3/A (5), D (5), DEFA14A (5), S-3 (5), SC 13G/A (5), S-8 (4), SC 13D (4), 4/A (3), ARS (3), CT ORDER (3), NT 10-K (3), PRE 14A (3), S-1 (3), SC 13D/A (3), SCHEDULE 13G (3), 424B3 (2), 8-A12B (2), S-4/A (2), 25-NSE (1), 424B4 (1), 8-A12B/A (1), CERT (1), CERTNAS (1), DEF 14C (1), DEFR14A (1), PRE 14C (1), S-3/A (1), S-4 (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Oct 31, 2025
    Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareXBIONasdaq

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).7

Risk factors and legal proceedings

The risks Xenetic Biosciences (United States) names in Item 1A of its 10-K filed Mar 12, 2026: 67 risks under these headings, as written.7

  • Risks Related to Our Financial Condition and Capital Requirements
  • We have never been profitable and may never achieve or sustain profitability. If we are unable to generate sufficient revenue from our operations to pay expenses or we are unable to obtain additional financing on commercially reasonable terms, our business, financial condition and results of operations may be materially and adversely affected.
  • We will require substantial additional funding to achieve our goals. Failure to obtain this necessary capital when needed on acceptable terms, or at all, may force us to delay, limit or terminate our product development efforts, other operations or commercialization efforts.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.
  • Risks Related to the Discovery and Development of our Pharmaceutical Products
  • Our business is substantially dependent on the success of the DNase technology.
  • We are an early stage company in the business of developing pharmaceutical products including drug candidates and technologies. Given the uncertainty of such development, our business operations may never fully materialize and create value for investors.
  • We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of our pharmaceutical products.
  • We may encounter substantial delays in commencement, enrollment or completion of our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing our current and future drug candidates on a timely basis, if at all.
  • If we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a drug candidate, or the approval may be for a more narrow indication than we expect.
  • If we obtain regulatory approval for a drug candidate, our drug candidate will remain subject to regulatory scrutiny.
  • The commercial success of any current or future pharmaceutical products will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.
The other 57 risks
  • The commercial potential of a pharmaceutical candidate in development is difficult to predict. If the market size for a new drug candidate or technology is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.
  • Failure to obtain or maintain adequate coverage and reimbursement for our drug candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
  • We may use our financial and human resources to pursue a particular research program or drug candidate and fail to capitalize on programs or drug candidates that may be more profitable or for which there is a greater likelihood of success.
  • We may not be successful in our efforts to identify or discover additional pharmaceutical products.
  • The market opportunities for our drug candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
  • Clinical trials may fail to demonstrate the safety and efficacy of our pharmaceutical drug candidates and could prevent or significantly delay regulatory approval.
  • We may fail to obtain orphan drug designations from the FDA for our drug candidates, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • Risks Related to Our Reliance on Third-Parties
  • If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies.
  • We expect to rely on third parties to conduct, supervise and monitor our clinical studies, and if these third parties perform in an unsatisfactory manner, it may harm our business.
  • Our collaborators or strategic partners may decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products.
  • We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.
  • We are a party to certain collaboration agreements, and may enter into one or more collaborations in the future, pursuant to which we may be required to relinquish important rights to and control over the development of our drug candidates or otherwise be subject to unfavorable terms.
  • We have no manufacturing, sales, marketing or distribution capabilities, and we may have to invest a significant amount of resources to develop these capabilities.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • Our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.
  • Risks Related to Our Intellectual Property
  • If we fail to adequately protect or enforce our intellectual property rights, we may be unable to operate effectively.
  • Issued patents covering our drug candidates could be found invalid or unenforceable if challenged in court.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If we infringe on the intellectual property rights of others, our business and profitability may be adversely affected.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Our inability to protect our confidential information and trade secrets would harm our business and competitive position.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Risks Related to Our Business Operations
  • We may not be successful in identifying and implementing any potential strategic alternatives in a timely manner, or at all, and the strategic review process and any strategic transactions that we may consummate could have negative consequences.
  • We operate in an extremely competitive environment and there can be no assurances that competing technologies would not harm our business development.
  • Our future success depends on our ability to retain principal members of our executive team, consultants and advisors and to attract, retain and motivate qualified personnel.
  • We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.
  • We are a party to collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.
  • Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay collaborators and others.
  • Potential new accounting standards or legislative actions may adversely impact our future financial position or results of operations.
  • Risks Related to Our Common Stock
  • We may not continue to meet the continued listing requirements of Nasdaq, which could result in a delisting of our common shares.
  • The market price of our securities may be highly volatile, and you may not be able to sell our securities.
  • Actions of activist shareholders could cause us to incur substantial costs, divert management's attention and resources, and have an adverse effect on our business.
  • Our preferred stockholders have rights, preferences and privileges that are not held by, and are preferential to, the rights of our common stockholders, which could result in the interests of our preferred stockholders differing from those of our common stockholders.
  • The issuance of future shares of common stock may result in dilution to our stockholders.
  • We could be subject to securities class action litigation.
  • An active, liquid and orderly market for our common stock may not develop.
  • We have entered into agreements with our stockholders.
  • We do not intend to pay dividends on our common stock or preferred stock so any returns will be limited to the value of our stock.
  • Certain provisions of our Articles of Incorporation, Bylaws, and the Nevada Revised States may be deemed to have an anti-takeover effect, which could cause the market price of our common stock to decline.
  • General Risk Factors
  • We face potential product liability claims, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our drug candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our drug candidates, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.
  • Our financial condition, results of operations, business and cash flow may be negatively affected by unfavorable U.S. or global economic conditions.
  • Our ability to use potential future operating losses and our federal and state net operating loss (“NOL”) carryforwards to offset taxable income from revenue generated from operations or corporate collaborations could be limited.
  • Tax reform may significantly affect the Company and our stockholders.
  • Governments may impose price controls, which may adversely affect our future profitability.
  • Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • Use of our drug candidates could be associated with adverse side effects.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Non-cash charges such as share-based payments may adversely impact our results of operations.
  • Varying interpretations of existing accounting standards and rules have occurred with frequency and may cause us to have to restate previously reported result of operations.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • Failure in our information technology systems or those of our third-party service providers, including by cybersecurity attacks or other data security incidents, could significantly disrupt our operations.
  • We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.

Legal proceedings

From time to time, we may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

There are no matters, as of December 31, 2025, that, in the opinion of management, might have a material adverse effect on our financial position, results of operations or cash flows.

The opening of Item 3, Legal Proceedings.7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54